Xperix, an artificial intelligence (AI)-based solution company, announced on the 15th that it has taken the lead in the global AI healthcare market by acquiring Bagel Labs, the world’s first digital treatment (DTx) company to build a digital convergence drug commercialization model. In particular, Xperix plans to further accelerate the obesity digital convergence drug business, which is currently undergoing research and development in collaboration with Hanmi Pharmaceutical, and establish itself as an AI healthcare company that achieves practical results beyond market expectations.
Xperix secures management rights and largest shareholder status through the acquisition of Bagel Labs, and seeks to expand into a new business field called healthcare based on the successful experience of its existing AI business. Beyond simple business diversification, this is a strategic move that combines Xperix’s AI technology and Bagel Labs’ medical expertise to create synergy.
To this end, Bagel Labs CEO Park Soo-hong joined Xperix as an in-house director and chief AI officer (CAIO), and Samsung Medical Center orthopedic professor Moon Young-wan as an outside director. Through this personnel appointment, Xperix will strengthen technology and clinical reliability and internalize the entire process from clinical verification to commercialization.
Park Soo-hong, the new CAIO, is an AI and automation systems expert who has obtained Biomechanics and Applied Mathematics from Johns Hopkins University in the United States and a Ph.D. in engineering from Cambridge University in the United Kingdom. He will lead Xperix’s AI healthcare business based on his experience in developing an image recognition-based process automation system while working at Corning Precision Materials and commercializing digital treatments gained through the start-up of Bagel Labs.
Outside director Moon Young-wan is the nation’s top authority in the knee joint field, currently serving as the head of the bone joint center and the head of the medical department at Samsung Medical Center. Based on the experience of actively introducing advanced medical technologies such as robotic artificial joint surgery into clinical practice, it is expected to add depth to Xperix’s medical expertise.
“This acquisition is an important first step in expanding AI technology into the healthcare sector,” said Yoon Sang-chul, CEO of Xperix. “Starting with research and development of obesity digital convergence drugs that are already producing tangible results with Hanmi Pharmaceutical, we will open a new paradigm for personalized healthcare by combining proven platforms and world-class experts.”
With this acquisition, Xperix plans to become a global market leader by accelerating the development of AI healthcare products, including chronic disease management solutions.
Reporter Lee Sang-gyu